Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975777 | 0.85 | SMN1; SMN2 (0.42) | CA1CA2CA9CA12CA4 | |
| SCHEMBL546386 | 0.80 | CES2 (0.45) | CA1CA2CA9CA4SMN1; SMN2 | |
| SCHEMBL13118694 | 0.77 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1TP53NPC1S1PR2 | |
| SCHEMBL563505 | 0.77 | HSD11B1 (0.47) | SMN1; SMN2ALDH1A1TP53NPC1S1PR2 | |
| SCHEMBL65095 | 0.74 | SMN1; SMN2 (0.46) | CA1CA2CA9CA12CA4 | |
| SCHEMBL9010850 | 0.74 | CA2 (0.49) | CA1CA2CA9CA4SMN1; SMN2 | |
| SCHEMBL9010789 | 0.74 | MAOB (0.37) | CA1CA2CA9CA12CA4 | |
| SCHEMBL21595092 | 0.74 | ALDH1A1 (0.52) | CA9CA12SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL8637821 | 0.74 | KMT2A (0.53) | CA1CA2CA9CA4SMN1; SMN2 | |
| SCHEMBL1089508 | 0.74 | HSD11B1 (0.41) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981922-B2 | Synthesis of lactams | G1 THERAPEUTICS, INC. | 2021-04-20 | — | — | US | disclosed |
| US-20190119293-A1 | Synthesis of Lactams | G1 THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10202392-B2 | Synthesis of lactams | G1 THERAPEUTICS, INC. | 2019-02-12 | — | — | US | disclosed |
| US-20160257688-A1 | Process for Synthesis of Lactams | CHEMOGENICS BIOPHARMA | 2016-09-08 | — | — | US | disclosed |
| WO-2015061407-A1 | PROCESS FOR SYNTHESIS OF LACTAMS | TAVARES FRANCIS XAVIER (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20150087831-A1 | SYNTHESIS OF LACTAMS | G1 THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| EP-2841417-A1 | SYNTHESIS OF LACTAMS | Tavares, Francis Xavier (US) | 2015-03-04 | — | — | EP | disclosed |
| CN-104302620-A | Synthesis of lactams | TAVARES FRANCIS XAVIER | 2015-01-21 | — | — | CN | disclosed |
| WO-2013163239-A1 | SYNTHESIS OF LACTAMS | TAVARES FRANCIS XAVIER (US) | 2013-10-31 | — | — | WO | disclosed |
| US-6689890-B2 | Efficient lactam synthesis | UNIVERSITY OF SOUTH FLORIDA | 2004-02-10 | — | — | US | disclosed |
| US-20030171599-A1 | Efficient lactam synthesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-09-11 | — | — | US | disclosed |
| US-20030004337-A1 | Efficient lactam synthesis | SOUTH FLORIDA, UNIVERSITY OF | 2003-01-02 | — | — | US | disclosed |
| WO-2001083446-A1 | EFFICIENT LACTAM SYNTHESIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981922-B2 | Synthesis of lactams | HAAO, AGL, GALNT10 | CA1 268/4885CA2 445/4885CA9 98/4885 |
| US-10202392-B2 | Synthesis of lactams | HAAO, AGL, GALNT10 | CA1 268/4885CA2 445/4885CA9 98/4885 |
| US-20150087831-A1 | SYNTHESIS OF LACTAMS | HAAO, AGL, GALNT10 | CA1 268/4885CA2 445/4885CA9 98/4885 |
| US-20030004337-A1 | Efficient lactam synthesis | COASY, RCE1, DHPS | CA1 20/4885CA2 243/4885CA9 1375/4885 |
| US-20030171599-A1 | Efficient lactam synthesis | COASY, APH1A, CIAPIN1 | CA1 32/4885CA2 412/4885CA9 1923/4885 |
| US-20160257688-A1 | Process for Synthesis of Lactams | AGL, HAAO, GALNT10 | CA1 212/4885CA2 412/4885CA9 131/4885 |
| US-20190119293-A1 | Synthesis of Lactams | HAAO, AGL, GALNT10 | CA1 268/4885CA2 445/4885CA9 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.